Apellis Pharma
Apellis Pharmaceuticals, often referred to simply as Apellis, is a leading biopharmaceutical company headquartered in the United States. Founded in 2009, the company has made significant strides in the field of complement biology, focusing on innovative therapies for rare diseases and serious conditions. With a strong operational presence in North America and Europe, Apellis is dedicated to transforming the treatment landscape for patients with unmet medical needs.
The company’s flagship product, pegcetacoplan, is a groundbreaking therapy designed to address conditions such as paroxysmal nocturnal haemoglobinuria (PNH) and geographic atrophy (GA) associated with age-related macular degeneration. Apellis stands out in the industry for its commitment to advancing complement inhibition, positioning itself as a pioneer in this specialised area. With a robust pipeline and a focus on patient-centric solutions, Apellis Pharmaceuticals continues to solidify its reputation as a key player in the biopharmaceutical sector.
-19 vs industry average
Apellis Pharma’s score of 20 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Apellis Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Reported emissions
No reported emissions data is available for Apellis Pharma yet.
Apellis Pharma's reported carbon emissions
Apellis Pharma, headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges available from the company.
As a result, Apellis Pharma's climate commitments and initiatives remain unclear, and there is no inherited emissions data from a parent company or corporate family. The company may still be in the process of developing its sustainability strategies or reporting frameworks.
In the context of the pharmaceutical industry, many companies are increasingly focusing on reducing their carbon footprints and setting science-based targets to align with global climate goals. However, without specific data or commitments from Apellis Pharma, it is challenging to assess their current standing in this regard.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Apellis Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Apellis Pharma yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Apellis Pharma
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project